Alvogen has more than 200 pharmaceutical products in development and registration, with over 80 products expected to be launched in 2011.  The group's product portfolio consists of a broad range of leading molecules for the treatment of conditions in the areas of oncology, cardiology, respiratory, neurology and gastroenterology. Contact local and regional sales representives.

With more than 120 years in operation, the company has become a successful, full-service pharmaceutical manufacturer of Rx and OTC products for the U.S., E.U. and international markets with an unsurpassed regulatory compliance history.  Norwich Pharmaceuticals (NPI) is Alvogen's US manufacturing base, with annual capacity of over five billion tablets and capsules. Through a Lean Six Sigma process, the company focuses on continuous improvement programs in NPI quality and customer service. Central Supply chain and quality teams outside the U.S. manage the flow of products from all around the world to ensure high quality and fast-to-market service to meet global market demands.

We focus on difficult-to-make and high-value formulations and pursue first-to-file opportunities. Our product pipeline is filled by selections from internal R&D candidates, in-licensed products, fostering strategic partnerships and targeted portfolio acquisitions. We are creative in our product selection process and our approach to R&D project milestone management is very disciplined. 

We strive to build a dependable network of partners around the world to support manufacturing, product development, supply chains and sales.